key: cord-0876857-lxhuzhmw authors: McEvoy, Natalie L.; Clarke, Jennifer L.; Mc Elvaney, Oliver J.; Mc Elvaney, Oisin F.; Boland, Fiona; Hyland, Deirdre; Geoghegan, Pierce; Donnelly, Karen; Friel, Oisin; Cullen, Ailbhe; Collins, Ann M.; Fraughen, Daniel; Martin-Loeches, Ignacio; Hennessy, Martina; Laffey, John G.; Mc Elvaney, Noel G.; Curley, Gerard F. title: A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial date: 2021-04-19 journal: Trials DOI: 10.1186/s13063-021-05254-0 sha: d9b3674dee07fad68b72715fdfc0d5587222e284 doc_id: 876857 cord_uid: lxhuzhmw OBJECTIVES: The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolastin®(plasma-purified alpha-1 antitrypsin) reduces circulating plasma levels of interleukin-6 (IL-6). Secondary objectives are to determine the effects of intravenous Prolastin® on important clinical outcomes including the incidence of adverse events (AEs) and serious adverse events (SAEs). TRIAL DESIGN: Phase 2, randomised, double-blind, placebo-controlled, pilot trial. PARTICIPANTS: The study will be conducted in Intensive Care Units in hospitals across Ireland. Patients with a laboratory-confirmed diagnosis of SARS-CoV-2-infection, moderate to severe ARDS (meeting Berlin criteria for a diagnosis of ARDS with a PaO(2)/FiO(2) ratio <200 mmHg), >18 years of age and requiring invasive or non-invasive mechanical ventilation. All individuals meeting any of the following exclusion criteria at baseline or during screening will be excluded from study participation: more than 96 hours has elapsed from onset of ARDS; age < 18 years; known to be pregnant or breastfeeding; participation in a clinical trial of an investigational medicinal product (other than antibiotics or antivirals) within 30 days; major trauma in the prior 5 days; presence of any active malignancy (other than nonmelanoma skin cancer) which required treatment within the last year; WHO Class III or IV pulmonary hypertension; pulmonary embolism prior to hospital admission within past 3 months; currently receiving extracorporeal life support (ECLS); chronic kidney disease receiving dialysis; severe chronic liver disease with Child-Pugh score > 12; DNAR (Do Not Attempt Resuscitation) order in place; treatment withdrawal imminent within 24 hours; Prisoners; non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available; IgA deficiency. INTERVENTION AND COMPARATOR: Intervention: Either a once weekly intravenous infusion of Prolastin® at 120mg/kg of body weight for 4 weeks or a single dose of Prolastin® at 120mg/kg of body weight intravenously followed by once weekly intravenous infusion of an equal volume of 0.9% sodium chloride for a further 3 weeks. Comparator (placebo): An equal volume of 0.9% sodium chloride intravenously once per week for four weeks. MAIN OUTCOMES: The primary effectiveness outcome measure is the change in plasma concentration of IL-6 at 7 days as measured by ELISA. Secondary outcomes include: safety and tolerability of Prolastin® in the respective groups (as defined by the number of SAEs and AEs); PaO(2)/FiO(2) ratio; respiratory compliance; sequential organ failure assessment (SOFA) score; mortality; time on ventilator in days; plasma concentration of alpha-1 antitrypsin (AAT) as measured by nephelometry; plasma concentrations of interleukin-1β (IL-1β), interleukin-8 (IL-8), interleukin-10 (IL-10), soluble TNF receptor 1 (sTNFR1, a surrogate marker for TNF-α) as measured by ELISA; development of shock; acute kidney injury; need for renal replacement therapy; clinical relapse, as defined by the need for readmission to the ICU or a marked decline in PaO(2)/FiO(2) or development of shock or mortality following a period of sustained clinical improvement; secondary bacterial pneumonia as defined by the combination of radiographic findings and sputum/airway secretion microscopy and culture. RANDOMISATION: Following informed consent/assent patients will be randomised. The randomisation lists will be prepared by the study statistician and given to the unblinded trial personnel. However, the statistician will not be exposed to how the planned treatment will be allocated to the treatment codes. Randomisation will be conducted in a 1:1:1 ratio, stratified by site and age. BLINDING (MASKING): The investigator, treating physician, other members of the site research team and patients will be blinded to treatment allocation. The clinical trial pharmacy personnel and research nurses will be unblinded to facilitate intervention and placebo preparation. The unblinded individuals will keep the treatment information confidential. The infusion bag will be masked at the time of preparation and will be administered via a masked infusion set to maintain blinding. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 36 patients will be recruited and randomised in a 1:1:1 ratio to each of the trial arms. TRIAL STATUS: In March 2020, version 1.0 of the trial protocol was submitted to the local research ethics committee (REC), Health Research Consent Declaration Committee (HRCDC) and the Health Products regulatory Authority (HPRA). REC approval was granted on April 1(st) 2020, HPRA approval was granted on April 24(th) 2020 and the HRCDC provided a conditional declaration on April 17(th) 2020. In July 2020 a substantial amendment (version 2.0) was submitted to the REC, HRCDC and HPRA. Protocol changes in this amendment included: the addition of trial sites; extending the duration of the trial to 12 months from 3 months; removal of inclusion criteria requiring the need for vasopressors; amendment of randomisation schedule to stratify by age only and not BMI and sex; correction of grammatical error in relation to infusion duration; to allow for inclusion of subjects who may have been enrolled in a clinical trial involving either antibiotics or anti-virals in the past 30 days; to allow for inclusion of subjects who may be currently enrolled in a clinical trial involving either antibiotics or anti-virals; to remove the need for exclusion based on alpha-1 antitrypsin phenotype; removal of mandatory isoelectric focusing of plasma to confirm Pi*MM status at screening; removal of need for mandatory echocardiogram at screening; amendment on procedures around plasma analysis to reflect that this will be conducted at the central site laboratory (as trial is multi-site and no longer single site); wording amended to reflect that interim analysis of cytokine levels taken at 7 days may be conducted. HRCDC approved version 2.0 on September 14th 2020, and HPRA approved on October 22nd 2020. REC approved the substantial amendment on November 23(rd). In November 2020, version 3.0 of the trial protocol was submitted to the REC and HPRA. The rationale for this amendment was to allow for patients with moderate to severe ARDS from SARS-CoV-2 with non-invasive ventilation. HPRA approved this amendment on December 1st 2020 and the REC approved the amendment on December 8th 2020. Patient recruitment commenced in April 2020 and the last patient will be recruited to the trial in April 2021. The last visit of the last patient is anticipated to occur in April 2021. At time of writing, patient recruitment is now complete, however follow-up patient visits and data collection are ongoing. TRIAL REGISTRATION: EudraCT 2020-001391-15 (Registered 31 Mar 2020). FULL PROTOCOL: The full protocol (version 3.0 23.11.2020) is attached as an additional file accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05254-0. A randomized double-blind placebo-controlled, pilot trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Prolastin Placebo 0.9% sodium chloride Phase of trial: Objectives: The primary objective is to demonstrate a biological effect of IV Prolastin administered weekly at 120mg per kilogram of body weight in patients with severe COVID-19 illness requiring intubation and mechanical ventilation for ARDS by reducing circulating levels of IL-6 as measured by plasma ELISA. The secondary objectives of this study are: In order to be eligible to participate in this study, an individual must meet all of the following inclusion criteria: In early December 2019, multiple pneumonia cases of unknown origin were identified in Wuhan, the capital city of Hubei province, China. The inciting pathogen was subsequently identified as a novel enveloped RNA betacoronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or, colloquially, COVID-19. The World Health Organization (WHO) has recently declared COVID-19 a public health emergency of international concern. As of March 30, 2020, more than 750,000 laboratory-confirmed cases have been documented globally, with over 36,000 deaths. In Ireland, there have been over 2,800 confirmed cases to date, with 46 deaths. These numbers are expected to grow substantially in the coming weeks, as testing becomes more widely available and a critical mass of infected individuals leads to patient overflow from hospitals into the community. Early data from clinical and research facilities in both China and Italy indicate that following the introduction of formalized testing programmes, the number of diagnosed cases rises exponentially. This in turn results in bed capacity in healthcare facilities being exceeded. Availability of critical care medicine (intensive care unit, critical care unit, coronary care unit) is limited by a scarcity of ventilators, invasive monitoring equipment, specialist staff and critical care beds. The projected increase in diagnosed cases in Ireland is 30% per day, with an estimate of 10-15,000 cases by the end of this month (March). The reported proportion of patients unwell enough to require ICU support is 6-14%. The median time spent on a ventilator by an infected patient requiring ICU support is 7 days. Ireland currently has less than 300 ICU beds. ARDS is a common condition of acute hypoxemic respiratory failure resulting from disruption of the alveolar-capillary barrier, and a resultant inflammatory pulmonary oedema. It can occur in the critically ill in response to many insults including severe trauma, burns, infection, major surgery or neurological disorders. ARDS is a leading cause of death and disability in critically ill adults and children worldwide 1, with a hospital mortality of approximately 40%. It is estimated that up to 20,000 cases of ARDS occur annually; 50% of these fall into the "moderate -severe" category of ARDS and have up to 40% mortality. ARDS confers a considerable long-term illness and disability burden on the individual sufferer and on society. Only 50% of survivors are able to return to work 12 months after hospital discharge, while cognitive, psychologic, and physical morbidity persists for up to 5 years. ARDS has significant resource implications, prolonging intensive care unit (ICU) and hospital stay, and requiring rehabilitation in the community, all of which stand to be impaired by the re-deployment of resources during the current pandemic. Prior to the emergence of COVID-19, patients with ARDS accounted for 10% of intensive care unit (ICU) admissions, and over a quarter of ICU bed-days. The rapid accumulation of COVID-associated ARDS cases both in Ireland and internationally will therefore lead to ICU capacity being exceeded. There are no specific treatments for ARDS, and management remains supportive with lungprotective ventilation and restrictive fluid management 8. Among patients who receive low tidal-volume ventilation, mortality rates remain unchanged over the past two decades highlighting the need for novel therapeutic strategies. Unsuccessful large scale clinical trials of multiple therapeutic strategies, including nitric oxide, anti-oxidants, surfactants, corticosteroids and immunomodulating agents such as IL-10 , GM-CSF, neutrophil elastase inhibitors, and high frequency oscillatory ventilation highlight the need for novel approaches for these patients. Most recently, statin therapy was found to be ineffective in 2 large trials, including the HARP-2 study of simvastatin. Therefore, innovative therapies are needed to reduce both the mortality associated with ARDS and the long-term morbidity in survivors. The trial population we propose to study includes any patient admitted to the ICU with moderate-to-severe ARDS secondary to COVID-19 (PaO2/FiO2 <200) Patients will where possible be matched for age. The intervention we propose to use is human plasma-purified alpha-1 antitrypsin (Prolastin, Grifols Pharmaceuticals, Germany). This medication has previously been administered to humans intravenously on a weekly basis to patients with alpha-1 antitrypsin (AAT) deficiency, graft-versus-host disease and severe panniculitis 1-5 . We propose to use a dose of 120mg/kg. This medication has an established safety profile at this dose (and also for more frequent administration) both in the clinical trial setting and in clinical practice. Briefly, the study aims to assess whether treatment with Prolastin results in decreased levels of pro-inflammatory cytokines, decreased inflammation and improved outcome in patients with COVID-19-associated ARDS. Little is known about the pre-hospital course of the disease. However, in-hospital studies have shown that COVID-19 induces excessive and aberrant non-effective host immune responses associated with severe lung injury 6 . Higher rates of ARDS are seen in elderly patients with comorbidities 7 . In China, although 80% had mild illness, approximately twenty five percent of those hospitalized needed ICU care, and for those in the ICU, mortality was 49%. Those with Acute Respiratory Distress Syndrome (ARDS) have a mortality of 52.4% 8, 9 . In those with COVID-19 infection and ARDS, severe systemic inflammation is also observed, with several key inflammatory cytokines the likely culprits, in particular interleukin (IL)-6 and IL-1β. Onset of this highly-proinflammatory state has been noted in several of the above A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 20 of 61 studies to occur prior to rapid clinical deterioration in the context of acute respiratory failure, ARDS, acute renal failure, shock and arrhythmia, all of which have are known to be related to upregulation of one or more of the above-mentioned cytokines. The risk of dying appears highest in those with older age, hypertension, diabetes and lower temperature. No antiviral or other drug has shown clinical efficacy in treating these individuals. Therapeutic options that have been proposed include steroids, intravenous immunoglobulin and selective cytokine blockade targeting two master pro-inflammatory cytokines involved in viral illness and ARDS -namely IL-1β and IL-6 -such as anakinra and tocilizumab 10 . Clinical trials with the combination lopinavir/ritonavir, remdesivir and tocilizumab are still ongoing. One recent randomized evaluation of lopinavir/ritonavir in 199 patients in China showed no benefit compared to placebo 11 . The evidence for the potential effectiveness of chloroquine is based on in vitro data and unpublished single arm studies in China, but nevertheless many centres are now using hydroxychloroquine on an off-label basis 10 . In one single arm study on 20 confirmed COVID-19 patients, treatment with hydroxychloroquine was associated with viral load reduction and this effect seemed to be reinforced by the combination with azithromycin 10 . Such empiric therapy conveys clear potential safety risks, therefore the priority should be recruitment of patients into well-designed clinical trials to ensure the assessment of safety and effectiveness of treatment options in addition to biological efficacy before proceeding to larger multi-centre studies. If the proposed intervention is successful, it would represent the first successful randomizedplacebo control trial in the field and the first clinically-proven treatment for severe COVID-19 illness beyond standard ICU management of ARDS. This would facilitate progression to a larger multi-centre study. The number of lives saved in the event of such a therapy proving efficacious with regard to clinical outcomes would conservatively stand in the hundreds of thousands, and potentially in the millions. One of the primary functions of AAT in the human body is to irreversibly bind neutrophil elastase (NE) an omnivorous serine protease release by activated or disintegrating neutrophils. NE levels and activity are markedly increased in the airways of patients with ARDS, and previous studies have shown that IV administration of AAT in humans results in augmented antielastase capacity of airway epithelial lining fluid, reduced NE activity in bronchoalveloar lavage fluid and decreased breakdown of lung tissue 1, 2, 4, 5 . While AAT chiefly inhibits NE, it also other exerts an antiprotease effect on chymotrypsin, cathepsin G (CathG) and proteinase 3 (PR3) 12 . The structure of the AAT is critical for its antiprotease activity and comprises 3 beta sheets (A, B and C), 9 alpha helices and a reactive center loop (RCL) at the C-terminal end 13 . A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. In addition to its antiprotease effects [14] [15] [16] , AAT is a potent anti-inflammatory and immunomodulator [17] [18] [19] [20] [21] . Of particular relevance to COVID-19, it has been shown to modulate suppress the production and activity of several key pro-inflammatory cytokines, including interleukin IL-1, IL-6, IL-8 and tumor necrosis factor (TNF)-α 17, 18, 22, 23 , while preserving the production of the anti-inflammatory cytokine IL-10 24 . AAT also binds a variety of proteins and fatty acids 25, 26 . Research investigating the impact of AAT on viral infections has demonstrated that HIV replication and T-cell numbers are associated with low serum levels of AAT and recent data indicate that AAT can inhibit HIV replication in T-cells as quantified by significant decreases in viral RNA and p24 epitope. This latter observation is thought in part due to the ability of AAT to enter T cell and impact upon IjBa ubiquitination 27 . A peptide derived from AAT has also been shown to display antiviral properties in response to HIV-1 infections -Munch, et al., 28 showed that the AAT viral inhibitory peptide (VIRIP) inhibited a variety of HIV-1 strains including those resistant to current antiretroviral drugs and demonstrated that VIRIP blocked HIV-1 entry by interacting with the gp41 fusion peptide. Plasma-purified AAT has been administered intravenously to patients with AATD since the 1980's in order to achieve plasma levels exceeding a protective threshold of 11µM 5 . The initial dose was 60mg/kg given once weekly but other doses trialled following that including 120mg/kg biweekly 29 and 250mg/kg every 28 days 30 . Each dosing regimen was safe and well tolerated. Plasma purified AAT (usually at a dose of 60mg/kg) has been shown to impair destruction of lung tissue and slow progression of emphysema in people with severe AATdeficiency 2, 4 . Patient outcomes from two major studies of patients following AAT augmentation therapy suggest that it appears well tolerated and is generally safe 31, 32 . Wencker, et al., 32 reported the trial of 443 augmentation therapy recipients, of whom 65 experienced a total of 124 adverse events. Most commonly encountered adverse reactions were relatively benign and self-resolving. These included chills, urticarial rashes, fatigue, nausea, and vomiting. Although specific adverse effects may be anticipated and specifically monitored for during therapy, the range of possible adverse effects is large, and new potentially unforeseeable effects remain possible. The trial data however are reassuring, given that 58,000 infusions resulted in only five severe adverse events (four patients suffered anaphylactic reactions and one patient developed congestive cardiac failure), all of which concluded with a complete recovery. Critically, no deaths or instances of hematologic viral transmission were observed. Stoller et al 31 reported on the NHLBI experience of 747 patients receiving weekly AAT augmentation therapy for a period of seven years. The overall rate of adverse events was low at 0.02 per patient-month, with 83% of patients reporting no events. There were a total of 720 recorded adverse events, the most common of which included headache (47%), dizziness (17%), nausea (9%), and dyspnoea (9%). A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. More recent data has shown that increasing the dosage of plasma purified AAT given to AATD patients not only increases the anti-protease protection but also significantly decreases inflammation across a wide spectrum of inflammatory pathways including many of the cytokines seen in critically ill patients with COVID-19 1 . AAT is also known to be an endogenous inhibitor of many pro-inflammatory cytokines associated with COVID-19 infection including interleukin-6, IL-1β and TNF-α. Indeed, we have recently shown that abrupt cessation of AAT augmentation therapy for patients with genetic AAT-deficiency results in alterations to immune cell metabolism, inflammasome activation, marked increases in levels of these specific aforementioned pro-inflammatory cytokines, and subsequent progression to respiratory failure (see supplementary appendix). Further systemic effects of high dose AAT administration include a dramatic effect in the treatment of panniculitis 33, 34 . In addition there are circumstances when AAT is present in the body in normal amounts but is inactivated, either by excess inflammation leading to oxidation, complexation or proteolytic cleavage 35 . The study is designed so that:  One out of 3 patients will receive placebo once weekly for 4 weeks,  One out of 3 patients will receive a single dose of plasma purified AAT at a dose of 120mg/kg of body weight via intravenous infusion followed by placebo once weekly for 3 weeks, and  One out of 3 patients will receive a once weekly dose of plasma purified AAT at a dose of 120mg/Kg once weekly for 4 weeks. This will be followed by an observational week for all study participants. The medication will be given intravenously as there are compelling data to show that AAT has systemic and lung anti-inflammatory effects 25, 26, 31, 34 . The dose of 120mg/kg was chosen given the half-life of AAT following intravenous administration which is 4.6 days. In the study of Campos, et al., 1 a 120mg/kg infusion resulted in an increase in AAT level by 22µM at the nadir just before the next infusion which in non-AAT deficient individuals would lead to an AAT level in plasma between 42-75µM at day 7 post infusion. The data we have from healthy control individuals with community acquired pneumonia is that their AAT level increases to 53 +/-18µM on acute presentation and falls to 28.4 +/-8.1µM at 10 days. In data generated from our ICU from patients with ARDS, those who died had a significantly lower AAT level than those who survived (please see supplementary appendix). This dose of 120mg/kg has been shown to decrease proinflammatory cytokines in peripheral blood and in the lungs 1 . In addition a similar dose regimen has been sued in refractory panniculitis to good effect. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. The study population chosen will be the most severely ill patients with COVID-19 for whom at the moment only supportive therapy is available. This group has acute respiratory distress syndrome (ARDS) and a mortality of >50% 8, 9 . Our hypothesis is that there is a systemic and local deficiency of active AAT in people with ARDS and specifically people with ARDS secondary to COVID-19. This condition is characterized by severe cytokinaemia particularly with IL-6. AAT is an inhibitor of IL-6 production in addition to its effects on other cytokines. AAT also expresses antiviral properties and inhibits many of the pro-inflammatory actions of those cytokines with particular emphasis on neutrophils and T-cells two for the major cell types thought to be central to the lung manifestations of COVID-19. The currently available treatments for COVID-19 associated ARDS are supportive. A variety of approaches have been tried but no antiviral or other specific medication is currently recommended. Therapeutic options that have been proposed, include steroids, intravenous immunoglobulin, selective cytokine blockade (e.g. anakinra or tocilizumab) and JAK pathway inhibition. Clinical trials with the combination lopinavir/ritonavir, remdesivir and tocilizumab are ongoing, but to date are not convincing. The evidence for the potential effectiveness of chloroquine is based on in vitro data and unpublished single arm studies in China. In contrast, AAT is a proven anti-inflammatory against many of the processes associated with COVID-19 lung disease. AAT has been extensively used in individuals with severe lung disease for the past 40 years. It has an exceptional safety record. In two major studies of patients with deficiency of AAT undergoing chronic AAT augmentation therapy, the therapy was shown to be well tolerated and generally safe 31, 32 . As stated in 9.3 above, Wencker, et al., 32 reported the trial of 443 augmentation therapy recipients, of whom 65 experienced a total of 124 adverse events. Most commonly encountered adverse reactions were relatively benign and self-resolving. These included chills, urticarial rashes, fatigue, nausea, and vomiting. Although specific adverse effects may be anticipated and specifically monitored for during therapy, the range of possible adverse effects is large, and new potentially unforeseeable effects remain possible. The trial data however are reassuring, given that 58,000 infusions resulted in only five severe adverse events (four patients suffered anaphylactic reactions and one patient developed congestive cardiac failure), all of which concluded with a complete recovery. Critically, no deaths or instances of hematologic viral transmission were observed. Stoller et al 31 reported on the NHLBI experience of 747 patients receiving weekly AAT augmentation therapy for a period of seven years. The overall rate of adverse events was low at 0.02 per patient-month, with 83% of patients reporting no events. There were a total of 720 recorded adverse events, the most common of which included headache (47%), dizziness (17%), nausea (9%), and dyspnoea (9%). It is important to note however that the A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 24 of 61 data highlighted a lower rate of adverse events in participants receiving augmentation therapy less frequently than weekly. The rate of total adverse events decreased from 0.03 events per patient-month at weekly infusions to 0.024 events per patient-month at 2-3 weeks (P=0.020) and 0.005 events per patient-month at monthly infusions. Meyer et al (22) reported a very rare IgE anaphylactic reaction following the third intravenous infusion of AAT. Specific IgE antibodies against Prolastin-HS were identified on serum analysis of the patient. A second case has yet to be described in the literature. Although the usual dosage is 60mg/kg, recent large scale studies have evaluated safety in those receiving 120mg/Kg dosing. The largest of these studies evaluated the RAPID-RCT and RAPID-OLE studies in which biweekly infusions comprised 4.3% of all AAT and 5.2% of all placebo administrations across both studies 29 single patient and brain thrombus n=1). One of the 12 SAEs was considered to be drug related. The IMP may achieve clinical improvement in this patient cohort as augmenting the body's anti-inflammatory, antiprotease defenses with AAT may help the body withstand the enormous inflammatory attack which overwhelms the normal AAT response. The higher dosage is justified given our knowledge of the pharmacokinetics of plasma purified AAT, the need to achieve high levels in the circulation and lung and the published data on the enhanced anti-inflammatory effects with higher doses. We do not know the duration of treatment required. We have some data that a single high -dose of AAT may achieve the desired response but given the violent nature of the physiologic disturbances in COVID-19 ARDs we think it prudent to also include a more chronic dosing regimen. There is a possibility that by the time the patient is intubated with COVID-19 related ARDs we will have missed the opportunity to significantly interrupt an inflammatory process, which has begun and will continue unabated and that earlier intervention might be warranted. There is no evidence that the COVID-19 population will handle AAT differently than other populations but there is no COVID-19 specific data in that regard. Plasma purified AAT has frequently been administered in the presence of significant liver disease (another common manifestation of AAT deficiency) with no harmful side effects. It has also been administered to elderly patients with no need for dose adjustment and to immunocompromised individuals. There have been no specific studies of AAT administration in people with severe renal failure, although it is not a contraindication to its use. AAT is frequently administered to people with significant lung and liver disease who are on many concomitant medications. There are no known interactions. The risk for administering AAT to individuals with ARDS in the setting of COVID-19 is not a significant risk. This medication has a very high safety profile and will be administered in an institution with a very high expertise in this area. The medication is administered over approximately 60 minutes in a low volume. There is no specific training involved in its administration. It will be reconstituted by unblinded trial personnel just prior to administration. The potential benefits of this medication in this context is to see a decrease in the cytokinemia in these patients, with reversal or amelioration of the hemodynamic disturbances following from that. Prolastin is currently used worldwide, most notably for the treatment of people with genetic AAT-deficiency. Other similar preparations for augmentation include Aralast/Glassia (Baxter), and Zemira (CSL Behring), all of which are purified protein intravenous formulations taken from pooled human plasma. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. While Prolastin has been given to humans successfully for over 40 years, and has an excellent safety profile, it is important to consider potential risks, however unlikely, pertaining to its use. -Because Prolastin is made from human blood, it may carry the risk of transmitting infectious agents. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. -There is also the possibility that unknown infectious agents may be present in such products -There will be an increase in plasma volume following intravenous administration of Prolastin. Caution should therefore be used in patients at risk for circulatory overload o Additionally, since market entry of Prolastin, occasional reports of the following events have been received: flu-like symptoms, allergic-like reactions, dyspnea, tachycardia, shortness of breath, bronchospasm, wheezing, urticaria, back pain, clamminess, sweating, diarrhea, and fatigue. Less frequently, the following have also been reported: hypotension, anxiety, cyanosis, swelling of hands and feet, angio-, facial and lip oedema, nasal congestion, sinusitis, abdominal pains or cramps, pallor, and weakness. Rare cases of transient increase in blood pressure or hypertension and chest pain have also been reported. o Given that the proposed use of Prolastin in this instance is off-label, a risk/benefit analysis has been conducted in advance of this application. The analysis concluded that the grave need for therapeutics in this critically ill cohort, combined with the excellent real-world safety profile of Prolastin, its predictable pharmacokinetics and pharmacodynamics, its clearly delineated dosage and route of administration, the pronounced anti-inflammatory effect demonstrated in previous off-label uses, and the biological plausibility of AAT as a means of reducing the inflammatory burden in these patients, outweighed the low likelihood of adverse events. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 27 of 61 It is hoped that participants receiving Prolastin will experience decreased inflammation and clinical improvement. In the longer term, scientific and medical knowledge gained in this study may enhance our understanding of the disease process and lead to much-needed treatments for severe COVID-19-associated illness, as described in 9.1 above. The aim of the study is to conduct a clinical trial of IV AAT as a prospective anti-inflammatory therapy for severely ill COVID-19 patients with ARDS requiring ICU admission. The primary objective is to demonstrate a biological effect of IV Prolastin administered weekly at 120mg per kilogram of body weight in patients with severe COVID-19 illness requiring intubation and mechanical ventilation for ARDS by reducing circulating levels of IL-6 as measured by plasma ELISA. The secondary objectives of this study are: The primary outcome to be assessed is the change in level of circulating IL-6 in plasma at 7 days as measured by ELISA. Secondary endpoints for this study are listed below. These endpoints are designed to inform a larger multi-centre study in the future, should biological anti-inflammatory efficacy be demonstrated in the present study. Larger number of participants would likely be required to detect an effect on many of these secondary endpoints. However, should the present study detect an effect of Prolastin therapy one one of the secondary endpoints, such a result would be of great importance to the international medical community. Secondary outcome measures: • Safety and tolerability of both once-off and weekly administration of IV AAT in the cohort Both the active drug and matching placebo (0.9% sodium chloride solution for infusion) will be prepared by unblinded trial personnel and then transferred to the ICU in a blinded fashion to be administered at the bedside by a blinded member of the trial team. This process will be further detailed in a trial specific SOP for IMP preparation and administration. Description of the study population: The trial population we propose to study is a critically unwell population, and includes any patient admitted to the ICU with moderate-to-severe ARDS secondary to COVID-19 (PaO2/FiO2 <200). Patients will where possible be matched for age. rather than abolished entirely, (2) the anti-inflammatory effect is more pronounced with repeated dosing, and (3) once-off dosing and repeated weekly dosing are equally safe. Phase of trial: This study constitutes a single-centre Phase 2 trial that will inform a larger multi-centre Phase 3 trial. The number of study groups/arms: There are 3 study groups Description of study groups/arms including sample size: Group 1 (n=12) will receive placebo once weekly for 4 weeks. Group 2 (n=12) will receive IV Prolastin at 120mg/kg once, and following 7 days will then receive placebo weekly for a further 3 weeks (a total of 4 weeks of AAT or placebo). Group 3 (n=12) will receive IV AAT at 120mg/kg weekly for 4 weeks Time to complete study enrolment: The projected time required to complete study enrolment is 12 months. Expected duration of subject participation: The expected duration of subject participation is 5 weeks, with the first 4 weeks involving patients receiving either drug or placebo. This will likely involve patients continuing to be involved in the study beyond their discharge from ICU. This is intentional, and is designed to assess these individuals for delayed decline, a key feature of the mortality associated with COVID-19 illness. Following completion of the study, patients will subsequently be offered follow-up in a dedicated post-COVID-19 clinic. Identification and specifics of administration of the study intervention: The intervention we propose to use is human plasma-purified alpha-1 antitrypsin (Prolastin, Grifols Pharmaceuticals, Germany). This medication is administered intravenously on a weekly basis to patients with alpha-1 antitrypsin (AAT) deficiency, graft-versus-host disease and severe panniculitis. We propose to use a dose of 120mg/kg. This medication has an established safety profile at this dose (and also for more frequent administration) both in the clinical trial setting and in clinical practice. The placebo will be 0.9% sodium chloride for infusion. Patients will continue to receive current standard of care treatment during the study. Both patients and clinical staff administering the drug/placebo will be unaware as to whether drug or placebo is being administered. Study investigators conducting lab-based experimental measurements will be unaware as to whether the samples they are performing measurements in are from patients who are receiving drug or those receiving placebo. Similarly they will be unaware of the clinical status or trajectories of these patients. Sequence and duration of all trial periods: The 3 groups will run in parallel. The study duration for each group is 5 weeks, beginning with 4 weeks of drug or placebo and ending with a week of no drug/placebo. Patients will continue to receive follow-up from the clinical team, and will also be offered follow-up via a dedicated post-COVID-19 follow-up clinic. enrolled if they satisfy inclusion/exclusion criteria. Demographic and clinical information will be collected from the medical chart record and pseudonymised before being transferred to a password protected encrypted spreadsheet stored on a password protected computer. The clinical data pertaining to a given patient will already be accessible to the patient's designated health care team. The overall clinical data set will be accessible to the study data controller, and to designated data processors. Blood will be taken from the patient during routine blood draws from an in-situ arterial line by the clinical team assigned to their care. Results of hospital blood tests undertaken as part of standard care will be monitored. At two-day intervals, an extra 10-15ml of blood will be taken for the purpose of plasma isolation. This entails centrifuging whole blood in lithium heparin tubes at 200 x g for 5minutes at room temperature and removing the plasma supernatant that results for storage at -80oC. Cytokine measurements (IL-1, IL-6, IL-8, sTNFR1 and IL-10) will be undertaken using ELISA in accordance with manufacturers instructions. Experiments will be conducted under BSL2 conditions by operators using personal protective equipment (PPE). Physiological parameters such as respiratory compliance and PaO2/FiO2 will be monitored as part of routine clinical care. Clinical outcomes (mortality, time on ventilator, shock, renal replacement therapy) will be recorded on a time-to-event basis. All biological and physiological results, as well as clinical outcomes, will be stored on a password protected encrypted spreadsheet, which is in turn stored on a secure server hosted by the data controller. Other protocol-specific details: For this study, a central hospital laboratory will be used for measurements undertaken as part of routine clinical care, a central treatment area with specialist staff will be used, the investigational products (drug/placebo) will be made up in a centralized unit by a trained practitioner, the statistical analysis will be undertaken by a neutral statistician not connected with the study team, and cytokine measurements and isoelectric focusing will be undertaken by blinded research scientists in a centralized research laboratory. Not applicable. In order to be eligible to participate in this study, an individual must meet all of the following criteria: Fulfilment of each criterion must be clearly evidenced (in lab reports or correspondence) and/or documented in the medical records. All individuals meeting any of these exclusion criteria at baseline or during screening will be excluded from study participation: 1. More than 96 hours from the onset of ARDS 2. Age < 18 years 3. Known to be pregnant or breastfeeding 4. Participation in a clinical trial of an investigational medicinal product within 30 days (other than antibiotics or anti-virals) 5. Major trauma in the prior 5 days 6. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last year 7. WHO Class III or IV pulmonary hypertension 8. Pulmonary embolism within past 3 months 9. Currently receiving extracorporeal life support (ECLS) 10. Chronic kidney disease receiving dialysis 11. Severe chronic liver disease with Child-Pugh score > 12 12. DNAR (Do Not Attempt Resuscitation) order in place 13. Treatment withdrawal imminent within 24 hours 14. Prisoners 15. Non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available. 16 . Enrolled in a concomitant clinical trial of a medicinal product (other than antibiotics or anti-virals) 17. IgA deficiency The population of interest in this study is severely ill COVID-19 patients with ARDS requiring ICU admission. Participants will be screened daily in the ICU by the Investigator or Clinical Research Nurse. The investigator will determine those who are eligible to participate in accordance with the inclusion/exclusion criteria. It is the responsibility of the Investigator, or a person delegated by the Investigator to obtain written informed consent from each subject. Given that participants are critically unwell, they will be unable to provide consent to participate prior to enrolment. The Investigator or nominee will obtain assent from the next of kin as soon as possible. In the event that a participant regains capacity, the Investigator or nominee with obtain explicit informed A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 33 of 61 consent to continue in the study. The informed consent/assent procedure will involve adequate explanation of the aims, methods, anticipated benefits and potential hazards of the study. In the event that participants regain capacity they will be provided with a Regained Capacity Information Leaflet and will also need to sign the Regained Capacity Consent Form subject to a consent declaration by the Health Research Consent Declaration Committee. "Adequate time" must be given for consideration by the patient and/or next of kin. The PI must record when the patient information leaflet (PIL) was given to the patient/next of kin. The Investigator or designee will explain that the patients are under no obligation to enter the trial and that they can withdraw at any time during the trial, without having to give a reason for withdrawal. Where any participant is enrolled and does not regain competency (due to their death or neurological impairment) the default position, subject to local laws and ethical review processes, will be that the enrolled person will continue to be a participant in the trial. A copy of the signed Informed Consent form will be given to the participant/next of kin. The original signed form will be retained at the study site and a copy placed in the medical notes. If new safety information results in significant changes in the risk/benefit assessment, the patient information leaflet will be reviewed and updated if necessary and subjects will be provided with the new PIL in a timely manner and consent obtained. Patients will be deemed suitable for inclusion by a member of the investigating team in the study at the bedside . Eligible patients will be randomised by unblinded trial personnel who are the only unblinded members of team involved in the study. Clinical details are relayed to the randomiser), who uses a software program to assign the patient to one of the 3 groups. The unblinded trial personnel hold the randomization list and treatment allocations. The Randomiser also makes up the IMP and will hand it to a blinded member of the trial team who will transfer it to the ICU or the ward to be administered by a blinded member of the trial team. The randomisation and IMP preparation process is detailed in a study specific SOP. The study code should only be broken for valid medical or safety reasons e.g. in the case of a severe adverse event where it is necessary for the investigator or treating health care professional to know which treatment the patient is receiving before the participant can be treated. Subject always to clinical need, where possible, members of the research team should remain blinded. The code breaks for the trial are held by the unblinded trial personnel who are the only unblinded members of the team involved in the study. These will be kept in a password protected file accessible only by the unblinded personnel. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. In the event a code is required to be unblinded a formal request for unblinding will be made by the Investigator/treating health care professional. If the person requiring the unblinding is a member of the Investigating team then a request to the holder of the code break envelope/list, or their delegate will be made and the unblinded information obtained. If the person requiring the unblinding is not the CI/PI then that health care professional will notify the Investigating team that an unblinding is required for a trial subject and an assessment to unblind should be made in consultation with the clinical and research teams. On receipt of the treatment allocation details the CI/PI or treating health care professional will deal with the participant's medical emergency as appropriate. The CI/PI documents the breaking of the code and the reasons for doing so on the data collection tool, in the site file and medical records. It should also be documented at the end of the study in any final study report and/or statistical report. The CI/Investigating team will notify the Sponsor in writing as soon as possible following the unblinding detailing the reasons. If the unblinding is the result of a serious adverse event SAE; the CI/PI must report the SAE to the sponsor within the timelines required by ICH GCP and the applicable legislations. In view of the small sample size and relatively short duration of the study, a DSMB is not appropriate. However, after the 10 th patient has been enrolled in the trial, an interim analysis will be carried out by the RCSI Statistician and data will be presented to two independent physicians, following which a decision regarding whether or not to proceed will be undertaken based on (1) safety and tolerability, and (2) the status of the primary endpoint. If a reported SAE appears to be a SUSAR, then the blinding should be broken (as per Section 14.3.1 above). Then three possibilities resulting from the procedure of unblinding must be considered:  If the product administered to the subject is the tested investigational medicinal product, the case should be reported by the Sponsor as a SUSAR to the relevant Competent Authority and the relevant Ethics Committees.  Events associated with placebo will usually not satisfy the criteria for a serious adverse drug reaction and therefore expedited reporting will not be required. However, if after unblinding, SUSARs are associated with placebo (e.g. reaction due to an excipient or impurity), it is the sponsor's responsibility to report such cases. illness. Protocol version 36, 23-Nov-2020. Page 40 of 61 The following samples will be processed at each hospital site laboratory:  Investigations ordered by the clinical team as part of clinical need, including but not limited to complete blood count, basic liver/renal/bone profile biochemistry, standard markers of inflammation such as C-reactive protein The following samples will be processed at each site and stored (as per the SOP for processing, storing and shipping laboratory samples). At the end of the trial, these samples will be shipped from each site and analysed at the RCSI respiratory research laboratory, a centralized laboratory for plasma processing from whole blood for the purpose of this study, located on the Beaumont Hospital campus:  AAT level  Plasma isolation  Isoelectric focusing of plasma  Cytokine measurements by ELISA The end of the trial will be defined as the last patient visit for the last patient enrolled to the trial. Participants will be able to withdraw from the study at any point without giving a reason. This will be explained in all information leaflets to the patient and/or next of kin. has a pH of 6.6 to 7.4, and is to be administered by the IV route. Each vial of lyophilized Prolastin will be reconstituted with 40 mL of Sterile Water for Injection (WFI). The placebo to be used in the study is 0.9% sodium chloride solution for infusion ("normal saline"). Composition: 9.0 g/l sodium chloride (NaCl) in sterile water for injection. Each ml contains 9 mg sodium chloride. mmol/l: Na+ : 154 Cl-: 154. pH: 4.5-7. Pharmaceutical form: Solution for infusion. Clear solution, free from visible particles. Preparations of placebo or active will be labelled, and then transferred to the ICU in a blinded fashion and will be administered at the bedside by a member of the clinical team. There are no restrictions on medicine or treatment in this study. Prolastin has no known drugdrug interactions. The same applies to 0.9% sodium chloride solution for infusion. Patients will receive usual care, which is to be founded on evidence-based medicine. Alpha1-proteinase inhibitor (human), commercially available as Prolastin, is a sterile, stable, lyophilized preparation of purified human AAT. Prolastin is prepared from pooled human plasma from healthy donors by modification and refinements of the Cohn cold ethanol plasma fractionation technique followed by a purification process. Prolastin contains small amounts of other plasma proteins, which may include IgA, haptoglobin, alpha1-acid glycoprotein, lipoprotein A-1, and albumin. Reconstituted Prolastin contains no preservatives, has a pH of 6.6 to 7.4, and is to be administered by the IV route. Each vial of lyophilized Prolastin will be reconstituted with 40 mL of Sterile Water for Injection (WFI). The placebo to be used in the study is 0.9% sodium chloride solution for infusion ("normal saline"). A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 42 of 61 Not applicable. In vitro and ex vivo studies: The in vitro and ex vivo antiprotease and anti-inflammatory properties of plasma-purified AAT in general, and Prolastin specifically, are numerous. The reviewer is directed to the review by Bergin et al. 36 . Animal pharmacology studies 37 . Pharmacokinetics: The half-life of Prolastin administered intravenously in rabbits was determined to be 20.1 hours. Pharmacodynamics: A series of studies was conducted in rats and rabbits to determine the effect of a single intravenous dose of Prolastin, 100 mg/kg, infused rapidly, 8 mL (168 mg)/min in rats and 6 mL (126 mg)/min in rabbits, on a number of clinical and biochemical parameters. Rats were studied both with and without an inhibitor of kininase II/angiotensin converting enzyme in order to potentiate any peptide-mediated cardiovascular effects which might be present. In rats, no significant cardiovascular or hematologic effects were observed, but a slight fall in fibrinogen 30 minutes following infusion of the Prolastin was noted. In rabbits, a marginal fall in leukocytes was observed, but this proved to be not statistically significant. No significant hematologic changes were detected. Acute Toxicity: The acute toxicity of IV Prolastin was determined in mice, rats, and rabbits and compared to the acute toxicity of the excipient control substance. At an infusion rate of 3 mL/min, the LD50 of Prolastin in mice was 150±6 mL/kg (3,750 mg/kg) and that of the control was >156 mL/kg. In rabbits, there was no indication of any toxicity at the highest dose of Prolastin tested, 20.7 mL/kg, which was infused at a rate of 6 mL/kg (517 mg/kg) although one of three rabbits each in the groups receiving 6.9 mL and 20.7 mL/kg, respectively, of Prolastin died during the observation period. These two deaths were not related to administration of alpha1-PI. An additional three rabbits were administered alpha1-PI at a dose of 20.7 mL/kg without any sign of adverse effect throughout the 14-day observation period. Subacute Toxicity: A series of rabbits also received Prolastin or excipient control substance, 9.1 mL/kg (227 mg/kg), administered intravenously at a rate of 6 mL/min, daily on five successive days. All rabbits in the study gained weight and there were no significant differences in weight gain on the 6th day or 33rd day of the study between animals receiving alpha1-PI compared to those receiving control substance. No significant hematologic abnormalities were noted on the 6th or 33rd days of the study following five consecutive days of administration of Prolastin. An unexplained decrease in the cholesterol level of animals receiving Prolastin was seen on day six in one series of animals but was not seen when repeated in another group. Two rabbits died during the course of the study, both of which were receiving Prolastin. One rabbit died on day 4, with diarrhea present, and its death was felt to be related to infection. The other rabbit died on day 27 (three weeks after A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 43 of 61 the infusion period) and histopathology revealed no probable cause of death. Overall, no effects directly ascribable to administration of Prolastin were detected in animals undergoing necropsy and histopathologic analysis on days 6 or 33 of the study. One of the primary functions of AAT in the human body is to irreversibly bind neutrophil elastase (NE) an omnivorous serine protease release by activated or disintegrating neutrophils that is responsible for destruction of lung tissue and drives airway inflammation 38-44 . NE levels and activity are markedly increased in the airways of patients with ARDS, and previous studies have shown that IV administration of Prolastin in humans results in augmented antielastase capacity of airway epithelial lining fluid, reduced NE activity in bronchoalveloar lavage fluid and decreased breakdown of lung tissue 1, 2, 4, 5 . While AAT chiefly inhibits NE, it also other exerts an antiprotease effect on chymotrypsin, cathepsin G (CathG) and proteinase 3 (PR3) 12 . The structure of the AAT is critical for its antiprotease activity and comprises 3 beta sheets (A, B and C), 9 alpha helices and a reactive center loop (RCL) at the C-terminal end 22 . In addition to its antiprotease effects [14] [15] [16] , AAT is a potent anti-inflammatory and immunomodulator [17] [18] [19] [20] [21] . Of particular relevance to COVID-19, it has been shown to modulate suppress the production and activity of several key pro-inflammatory cytokines, including interleukin IL-1, IL-6, IL-8 and tumor necrosis factor (TNF)-α 17, 18, 22, 23 , while preserving the production of the anti-inflammatory cytokine IL-10 24 . Furthermore, we have also shown that abrupt cessation of plasma-purified AAT augmentation therapy for patients with AATD results in alterations to immune cell metabolism, inflammasome activation, dangerous increases in levels of these specific aforementioned pro-inflammatory cytokines, and subsequent progression to respiratory failure (results in press). -Because Prolastin is made from human blood, it may carry the risk of transmitting infectious agents. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. -There is also the possibility that unknown infectious agents may be present in such products -There will be an increase in plasma volume following intravenous administration of Prolastin. Caution should therefore be used in patients at risk for circulatory overload The route of administration and dosage described have been successfully used in both the clinical trial and clinical practice settings, and shown to be both safe and efficacious in highrisk populations. At present, AAT can only be delivered via the IV or aerosol route. The IV administration described avoids the exposure hazard related to aerosolized administration in COVID-19 patients, thereby reducing the risk to the clinical team. The dose of Prolastin or placebo will not be modified during the study. *The rate of infusion may be modified to accommodate clinical need (e.g. if the patient is clinically overloaded and cannot tolerate additional fluid). The infusion rate may be slowed down and given over a longer period of time if required but the IMP must be infused within 3 hours of preparation (as per the Summary of Product Characteristics). Patients discharged from the ICU will receive the next scheduled dose on the ward that they are discharged to. Patients discharged from the hospital before receiving all scheduled doses will not receive the next scheduled dose. Preparation and labelling of the investigational medicinal products will be completed in accordance with the relevant guidelines and the Trial specific SOP for IMP preparation and administration. Administration of IMP to patients will be as per an IMP administration protocol and will be recorded in the IMP dispensing log and the medical notes. Each IMP infusion will be labelled with the approved clinical trial label. Text for labels used for IMP have been provided by the Sponsor (Appendix 1). The patency of IV access is formally tested pre-and-post administration of IMP. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 46 of 61 The precise amount of IMP required to conduct the study is already on-site and stored appropriately in the RCSI Smurfit building, Beaumont Hospital campus according to the storage conditions outlined in the SmPC. The IMP will be distributed to other clinical trial sites as per SOP 1: IMP Receipt, Preparation, Administration and Destruction. Prolastin is supplied by Grifols pharmaceuticals free of charge, on compassionate grounds. 0.9% sodium chloride solution for infusion is supplied by the hospital pharmacy at each clinical trial site. In the event of clinical overload, the rate of infusion will be slowed, as guided by central venous pressure (CVP; all patients in the ICU will have CVP monitoring in situ as part of standard care). In the event of an allergic, anaphylactoid or anaphylactic reaction to the IMP, the infusion will be discontinued and immediate review by immunology services will be arranged. N/A no compliance assessment for this study There are no arrangements in place for the IMP to be provided to trial subjects post trial participation. However, the manufacturer are willing to explore compassionate-use supply to these individuals should a clinical improvement occur in response to therapy. Each adverse event will be assessed for the following criteria: The adverse event does not interfere with the volunteer's daily routine, and does not require intervention; it causes slight discomfort Moderate The adverse event interferes with some aspects of the volunteer's routine, or requires intervention, but is not damaging to health; it causes moderate discomfort Severe The adverse event results in alteration, discomfort or disability which is clearly damaging to health The assessment of relationship of adverse events to the administration of IMP is a clinical decision based on all available information at the time of the completion of the case report form. The following categories will be used to define the causality of the adverse event: Definitely: There is clear evidence to suggest a causal relationship, and other possible contributing factors can be ruled out. Probably: There is evidence to suggest a causal relationship, and the influence of other factors is unlikely Possibly There is some evidence to suggest a causal relationship (e.g. the event occurred within a reasonable time after administration of the trial medication). However, the influence of other factors may have contributed to the event (e.g. the patient's clinical condition, other concomitant events). There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial medication). There is another reasonable explanation for the event (e.g. the patient's clinical condition, other concomitant treatments). There is no evidence of any causal relationship. Category Definition The reference document to be used by the Sponsor to assess expectedness of the event against the IMP. The reference document is the Summary of Product Characteristics (SmPC) for Prolastin (Appendix 2). It is important to note that SAEs that are not related to the IMP do not require an expectedness assessment and will not be reported to the Sponsor. The Principal Investigator (PI) should make an assessment of seriousness as defined in section 17.1. Collection, recording and reporting of reportable serious adverse events to the sponsor will be completed according to the RCSI Expedited Reporting SOP (Appendix 3) All serious adverse events will be recorded by the site staff in the hospital notes, the database and on the sponsor's SAE form. The Principal Investigator (PI) or appropriate designee is responsible for reporting all SAEs to RCSI Pharmacovigilance (Pharmacovigilance@rcsi.ie) within 24 hours of first becoming aware of the event (as per the RCSI Sponsor SOP on Expedited Safety Reporting). SAEs will be collected from the time of the subject's enrolment until the final study visit. SAEs that continue beyond the normal collection period (i.e., are ongoing at the time a subject exits the study) will be followed until resolution or until stabilized with sequelae. SAEs that begin after the subject's participation in the study is complete, but that the PI considers to be related to study drug, may be reported at any time. Reporting to the sponsor will be completed as per the sponsor's pharmacovigilance SOP (RCSI SOP for Expedited Safety Reporting). A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 51 of 61 Death will not be captured as a Serious Adverse Event. Death will be captured as an outcome. However, the cause of death may be captured as a Serious Adverse Event, unless it is judged to be related to disease progression as detailed above. The sponsor will notify the main REC and competent authority of all SUSARs. SUSARs that are fatal or life-threatening must be notified to the CA and REC within 7 calendar days after the sponsor has learned of them. Other SUSARs must be reported to the REC and CA within 15 calendar days after the sponsor has learned of them. The sponsor will provide the main REC and the competent authority with Development Safety Update Reports (DSUR) which will be written in conjunction with the trial team and the Sponsorship office. The report will be submitted within 60 days of the Developmental International Birth Date (DIBD) of the trial each year until the trial is declared ended. An annual progress report (APR) will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given, and annually until the trial is declared ended. The sponsor will prepare the APR. The effects of Prolastin therapy during pregnancy have not been studied in a clinical trial. However, Prolastin has been received by pregnant women since becoming commercial available. To date, no adverse events have been published in the literature. 0.9% sodium chloride solution for infusion is given routinely to pregnant patients in the ICU setting. Participants will undergo a formal pregnancy test at the screening visit. Pregnant and breastfeeding women are excluded from the study. If a pregnancy does occur during the trial, it will be reported to the Sponsor according to the RCSI Expedited Reporting SOP (Appendix 3). To date, there have been no reported cases of overdose for Prolastin or other plasmapurified AAT product. No data are available in regard to overdosage in humans. While not constituting and overdose, clinical overload from excessive volume should be avoided. Avoidance of overload will be facilitated by monitoring of clinical signs such as venous pressure and by slowing the rate of infusion as necessary. Overload may also be alleviated using diuretic therapy, a standard component of the management of patients with ARDS. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 52 of 61 If any urgent safety measures are taken the PI/Sponsor shall immediately and in any event no later than 3 days from the date the measures are taken, give written notice to the competent authority and the relevant REC of the measures taken and the circumstances giving rise to those measures. Any SAR related to the IMP will be reported to the Sponsor irrespective of how long after IMP administration the reaction has occurred. AEs considered related to the study medication as judged by an investigator or the sponsor will be followed until resolution or until the event is considered stable. All related AEs that result in a subject's withdrawal from the study or are present at the end of the study, should be followed up until a satisfactory resolution occurs A "serious breach" is a breach which is likely to effect to a significant degree -(a) the safety or physical or mental integrity of the subjects of the trial; or (b) the scientific value of the trial. The sponsor of a clinical trial shall notify the competent authority in writing of any serious breach of -(a) the conditions and principles of GCP in connection with that trial; or (b) the protocol relating to that trial, as amended from time to time, within 7 days of becoming aware of that breach. The sponsor will be notified immediately of any case where the above definition applies during the trial conduct phase. The sponsor's SOP on the 'Notification of violations, urgent safety measures and serious breaches' will be followed. All data will be handled in accordance with the applicable Data Protection legislation Trial documentation will not bear the subject's name or other personal identifiable data. A participant study number will be used for identification. Data will be pseudonymised. The pseudonymised data will be stored on an encrypted and password protected electronic file (spreadsheet). The password will be held by members of the trial team only so that stored data can only be accessed by those on the trial delegation log. The investigator site file will be maintained by the principal investigator in a secure, access controlled cabinet. Source documentation will include paper and electronic heath records. It will be the responsibility of the investigator to ensure the accuracy of all data entered in the trial database (spreadsheet). The delegation log will identify all those A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 53 of 61 personnel with responsibilities for data collection and handling, including those who have access to the trial database. A spreadsheet will be used for data entry. The medical chart will act as source data. The trial data will be pseudonymised and inputted onto a spreadsheet that is encrypted and password protected. This file will be stored on a secure server within RCSI (see Section 18.2). None of the pseudonymised data will be shared with third parties. The study investigators will be responsible for data entry and quality. The study statistician will perform data analysis (see Section 20.3) Archiving will be authorised by the Sponsor following submission of the end of study report. Records will be retained at a secure archiving facility following end of study report. Trial data will be retained for: · Essential documents : 10 years after completion of trial · the trial database: 10 years after completion of trial The chief investigator is responsible for the secure archiving of Investigator Site File essential trial documents and the trial database. Destruction of essential documents will require authorisation from the Sponsor. Dr. Fiona Boland is the trial statistician who will be responsible for all statistical aspects of the trial from design through to analysis and dissemination The primary effectiveness outcome measure, a continuous variable, is the change in IL-6 in plasma at 7 days as measured by ELISA. As this is a pilot study a formal sample size calculation has not been conducted. Sample sizes of between 12 per group and 25 per group have been recommended variously for pilot studies [45] [46] [47] . Following these broad recommendations and clinical experience, we chose a recruitment sample size of 36 (12 per group) to assess the safety and tolerability, and to explore the biological effect. The study sample size is sufficient to demonstrate a significant difference in patients receiving Prolastin versus patients receiving placebo. It is estimated that all participants will be recruited within 12 months. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 55 of 61 The data will be summarized using appropriate descriptive statistics with respect to demographic and baseline characteristics. A consort flow diagram will be presented also. Efficacy observations and measurements and safety observations and measurements will be summarized using appropriate descriptive statistics (n, mean, standard deviation, median, minimum, maximum) for quantitative data and contingency tables (frequencies and percentages) for qualitative data. Participants will be analysed according to the planned treatment they have been assigned to. No imputation of missing data is planned. All withdrawals, missing and spurious data will be explored and reported in the final report. As outlined above for the primary outcome measures, a similar approach will be conducted here. Appropriate descriptive statistics will be used to explore the data. Estimates and 95% confidence intervals will be reported. No other analyses planned. Randomisation will take place following baseline data collection. The randomisation list for each site will be prepared by the study statistician and will be communicated to the unblinded trial personnel responsible for randomisation. Participants will be randomised to study arms stratified by age only. Block randomisation is applied at site level aimed at achieving equal numbers in each study arm as far as possible. An interim analysis of cytokine levels taken at 7 days may be conducted at after 10 patients have been enrolled. A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. A 24-hour contact number will be available in the circumstances when unblinding is required. The principal investigator will document the breaking of the code, and the reasons for doing so. It is at the discretion of the treating clinician whether unblinding should occur. Overall, it is felt that unblinding will be an extremely unlikely event. Any compromises in blinding will be reported in the trial conclusion. Otherwise, study unblinding will only take place once the statistical analysis plan has been agreed by the trial team and the final database has been locked. . As outlined above, a full SAP will be prepared prior to final analysis. Any deviations from this SAP will be described and justified in the final report. Fiona Boland is the trial statistician who will be responsible for all statistical aspects of the trial from design through to analysis and dissemination. Due to the urgent nature and rapid progression of the crisis, the study may start recruitment before the SAP is finalised. The SAP will be written, reviewed and signed off as soon as is practical during the study. Ethics Committee Beaumont Hospital Beaumont Road Dublin 9. Health Research Consent Declaration Committee. The investigator(s)/ institution(s) will permit trial-related monitoring, audits, REC review, and regulatory inspection(s), providing direct access to source data/documents. Trial participants are informed of this during the informed consent discussion. Participants will consent to provide access to their medical notes. The sponsor will ensure that the trial protocol, patient information leaflet, informed consent form, GP letter and submitted supporting documents have been approved by the appropriate competent authority and a research ethics committee, prior to any patient recruitment. The protocol and all agreed substantial protocol amendments, will be documented and submitted for ethical and regulatory approval prior to implementation. Before the site can enrol patients into the trial, the Principal Investigator or designee must apply to the hospital for permission to conduct the study and be granted written permission. It is the responsibility of the Chief Investigator/ Principal Investigator or designee at each site to ensure that all subsequent amendments gain the necessary approval. This does not affect the individual clinician's responsibility to take immediate action if thought necessary to protect the health and interest of individual patients (see section 17.4.7 for reporting urgent safety measures). The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, doubleblind, placebo-controlled trial Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE) Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Rising to the Challenge of the Novel SARS-coronavirus-2 (SARS-CoV-2): Advice for Pulmonary and Critical Care and an Agenda for Research A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Proteases and antiproteases in chronic neutrophilic lung disease -relevance to drug discovery Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease Interaction of human alpha-1-proteinase inhibitor with neutrophil myeloperoxidase Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase alpha-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8 A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness The circulating proteinase inhibitor alpha-1 antitrypsin regulates neutrophil degranulation and autoimmunity Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals The BLT1 Inhibitory Function of alpha-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling Anti-inflammatory and immunomodulatory properties of alpha1-antitrypsin without inhibition of elastase Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood Glycosylation Repurposes Alpha-1 Antitrypsin for Resolution of Community-acquired Pneumonia Alpha1-antitrypsin, old dog Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency HIV replication in CD4+ T lymphocytes in the presence and absence of follicular dendritic cells: inhibition of replication mediated by alpha-1-antitrypsin through altered IkappaBalpha ubiquitination Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide Safety of biweekly alpha1-antitrypsin treatment in the RAPID programme Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group Unusual Acute Sequelae of alpha1-Antitrypsin Deficiency: A Myriad of Symptoms With One Common Cure Local impairment of anti-neutrophil elastase capacity in community-acquired pneumonia A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis Protease-antiprotease imbalance in the lungs of children with cystic fibrosis Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch Design and analysis of pilot studies: recommendations for good practice Recommendations for planning pilot studies in clinical and translational research The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency Status: Signed Transaction ID: CBJCHBCAABAAaxMlzonQZ9vt4mLsVAmF6rwikVqt9eT_ "Covid 19 AAT Trial Protocol Version 3 23Nov2020" History Document Document emailed to Gerard Curley (gercurley@rcsi.ie) for signature 2020-12-08 -8:47:12 PM GMT Email Document emailed to Maurice Dowling (mauricedowling@rcsi.ie) for signature 2020-12-08 -9:01:59 PM GMT Email viewed by Maurice Dowling (mauricedowling@rcsi.ie) Document e-signed by Maurice Dowling (mauricedowling@rcsi.ie) Agreement completed The following screening assessments will be undertaken to ensure that a patient meets the criteria for enrolment. Planned screening assessments as part of clinical trial (all to occur within previous 2 days):  Urine pregnancy test (for females of child bearing age)The following assessments will occur as part of routine care, and all will be performed within the previous 5 days (most recent results to be documented): Physical examination  Vital Signs (blood pressure, mean arterial pressure, heart rate, temperature, SaO2, urine output, respiratory rate (where appropriate)  Medical history (where possible)  Medical chart review  X-Ray  Electrocardiogram  Echocardiogram (where possible)  Laboratory assessments (blood count, basic liver/renal/bone profile biochemistry, standard markers of inflammation such as C-reactive protein)  Assessment of comorbidities  Confirmation of diagnosis of ARDS, requiring (1) acute onset; (2) PaO2/FiO2<200 regardless of positive end-expiratory pressure; (3) bilateral infiltrates seen on frontal chest radiograph; (4) pulmonary artery wedge pressure of 18 mmHg or less when measured or no clinical evidence of left atrial hypertension  Assessment of vasopressor requirement (target range 0.05-0.1μg/kg/min).Of note: The baseline visit will occur no later than 36 hours after the screening visit  The screening visit and baseline visit can occur on the same day  During the treatment phase, visits will occur +/-1 day of the scheduled date  The follow up period will be for 1 week after the final dose of IMP  The follow up visit after Early Discontinuation will be performed as soon as is possible.  Patients will continue to be followed by the clinical team and the post-COVID- 19 clinic thereafter.  Due to the nature of the study population, screen failures will not be re-considered for enrolment.A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020. Page 37 of 61  Eligibility determination following interpretation of results emanating from the screening process  Repeat review of medical history (where possible), medical chart  Repeat physical exam  Review of assessments carried out since screening visit by clinical team as part of routine care (these include, but are not limited to, radiology, electrocardiogram, echocardiogram, complete blood count, basic liver/renal/bone profile biochemistry, standard markers of inflammation such as C-reactive protein)  Vital Signs (blood pressure, mean arterial pressure, heart rate, temperature, SaO2, urine output, respiratory rate (where appropriate)  Current ventilation settings  Current vasopressor requirements  Review of concomitant medications (within the previous 7 days)  PaO2/FiO2 ratio  Respiratory compliance  SOFA score  Circulating AAT level  Isoelectric focusing on plasma samples to determine the phenotype.  Randomization NOTE: A plasma sample will be obtained for cytokine measurements following randomization (same day), and will be stored immediately Dose: 120mg/kg body weight intravenously once per week. These events may jeopardise the subject or may require an intervention to prevent one of the above characteristics/consequences. Such events should also be considered 'serious'. SUSAR Suspected Unexpected Serious Adverse Reaction A serious adverse reaction the nature and severity of which is not consistent with the information about the medicinal product in question set out: (a) in the case of a product with a marketing authorization, in the summary of product characteristics for that product, (b) in the case of any other investigational medicinal product, in the investigator's brochure relating to the trial in question. As this trial is recruiting in a population that is already in a life-threatening situation, it is expected that many of the patients will experience multiple AEs. In general, events that are expected in this population (i.e. events in keeping with the underlying condition) should not be reported as AEs / SAEs as they represent disease progression. All clinical events will be recorded in the medical record as per normal practice.The following adverse events will be collected:A. Adverse events of special interest (AESI) occurring within 2 hours of the start of infusion:1. New ventricular tachycardia (persistent tachycardia lasting > 30 minutes)* 2.Clinical scenario consistent with infusion reaction (e.g. urticaria, angioedema, new bronchospasm, anaphylaxis). Persistent hypotension lasting > 30 minutes and requiring intervention with vasopressors* 4.Persistent hypertension lasting > 30 minutes and requiring intervention with hypotensive agents* 5.Any event occurring within this time period which is considered by the investigator to be atypical in a patient with ARDS. *multiple episodes will be captured as one Adverse Event (AE) B. After the initial infusion period and until the patient is discharged from hospital, the following events will be recorded:A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020.Page 48 of 61AEs that are (in the opinion of the Investigator):• Atypical for a patient with ARDS • Unexpectedly severe or frequent for a patient with ARDS.• In line with the side effects outlined in the SmPC for Prolastin and not otherwise explained by the treated condition.Note -typical complications of ARDS, ventilation or treatment in the intensive care unit (including but not limited to multi-organ failure, pneumonia, urinary tract infection, sepsis etc.) will not be considered AEs.Events which meet the criteria in A or B will be recorded as AEs. AEs that also meet criteria for seriousness will be recorded as SAEs and will be reported to the Sponsor as outlined in Section 17.4.The investigator should attempt, if possible, to establish a diagnosis based on the subject's signs and symptoms. Where there is no diagnosis, symptoms will be recorded. When a diagnosis for the reported signs or symptoms is known, the investigator should report the diagnosis as the AE, rather than reporting the individual symptoms.All adverse events (i.e. AEs) will be recorded in the medical records, an AE or SAE form (as appropriate) and/or in the trial database (spreadsheet) following enrolment, in accordance with the protocol. All AEs should be treated appropriately. The following information will be recorded: description, date of onset and end date, severity, assessment of relatedness to the study medication, and action taken and outcome. Follow-up information should be provided as necessary.If the investigator suspects that the subjects' disease has progressed faster due to the administration of the IMP, then he will record and report this as an AE. It will be left to the investigator's clinical judgment whether or not an AE is of sufficient severity to require the subject's removal from treatment. A subject may also voluntarily withdraw from treatment due to what he or she perceives as an intolerable AE. If either of these occurs, the subject must undergo an end-of-study assessment and be given appropriate care under medical supervision until symptoms cease or the condition becomes stable. illness. Protocol version 36, 23-Nov-2020.Page 57 of 61Within 90 days after the end of the trial, the CI/Sponsor will ensure that the main REC and the competent authority is notified that the trial has finished. If the trial is terminated prematurely, those reports will be made within 15 days after the end of the trial. The sponsor will assign an independent monitor who will visit the investigator sites intermittently to validate compliance of the protocol to the GCP, the maintenance of the study related records, and the extensiveness and accuracy of a proportion of trial spreadsheet entries compared to source data (medical chart). The investigator will cooperate with the monitor to ensure that any potential discrepancies are resolved.Monitoring procedures include a remote site initiation visit designed to clarify all prerequisites before the trial commences at the site, interim site monitoring visits and study close-out visits. The study will be monitored by scheduled visits to site and on-going communication via telephone, video calls and e-mail with the investigator and research nurse.During on-site and remote monitoring visits the monitor may review; original patient records for the patient group; trial spreadsheet entries, drug accountability records; investigator site file and document retention. Study procedures will be observed by the monitor and any issues will be discussed with the PI or designee as necessary.Direct access to all source documents, where possible, must be guaranteed by the PI, who must provide support at all times for these activities. An application has been submitted to the HRB to support the trial. "RCSI holds insurance against claims from participants for injury caused by their participation in the clinical trial. However, as this clinical trial is being carried out in hospitals, each hospital continues to have a duty of care to the participant of the clinical trial. RCSI does not accept liability for any breach in the hospital's duty of care, or any negligence on the part of hospital employees. This applies whether the hospital is an HSE hospital or otherwise. Beaumont Hospital, Galway University Hospital, St James's University Hospital and Mater Misericordiae University Hospital selected to participate in this clinical trial shall provide clinical indemnity cover or relevant insurance for harm caused by their employees. All proposed publications will be discussed with Sponsor prior to publishing other than those presented at scientific forums/meetings. Please refer to the RCSI publication policy.A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness. Protocol version 36, 23-Nov-2020.Page 58 of 61 The trial will be conducted in compliance with the approved protocol, the ROI Regulations, ICH GCP E6 (R2) and the applicable regulatory requirement(s). Appendix